Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system

Thrombosis and Haemostasis

Volumn 100, Issue 6, 2008, Pages 1014-1020

  Soeda, Shinji ^a   Koyanagi, Satoru ^b   Kuramoto, Yukako ^a   Kimura, Masahiko ^a   Oda, Masatoshi ^a   Kozako, Tomohiro ^a   Hayashida, Satoru ^a   Shimeno, Hiroshi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Astrocytes; ERK related pathway; Neurotrophic factor; PC 12 cells; Plasminogen activator inhibitor 1

Indexed keywords

ANTIBODY; NERVE GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TYROSINE KINASE A ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ASTROCYTE; BRAIN; CELL STRAIN; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; HUMAN; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TISSUE;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASTROCYTES; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEURITES; NEURONS; PC12 CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RECEPTOR, TRKA; SIGNAL TRANSDUCTION;

EID: 57349155023     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0259     Document Type: Review

References (51)

1. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14: 1741-1745.
2. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
3. Juhan-Vague I, Vague P, Alessi MC, et al. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor-1. Diabetes Metab 1987; 13: 331-336.
4. Morange PE, Alessi MC, Verdier M, et al. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999; 19: 1361-1365.
5. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue - possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
6. Birgel M, Gottschling-Zeller H, Rohrig K, et al. Role of cytokines in the regulation of plasminogen activator inhibitor 1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-1687.
7. Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380.
8. Zirlik A, Leugers A, Lohrmann J, et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004; 91: 674-682.
9. Murakami M, Ikeda T, Saito T, et al. Transcriptional regulation of plasminogen activator inhibitor-1 by transforming growth factor-β, activin A and microphthalmia-associated transcription factor. Cellular Signalling 2006; 18: 256-265.
10. Jiang Z, Seo JY, Ha H, et al. Reactive oxygen species mediate TGF-?1-induced plasminogen activator inhibitor-1 upregulation in mesangical cells. Biochem Biophys Res Commn 2003; 309: 961-966.
11. Buisson A, Nicole O, Docagne F, et al. Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor β1. FASEB J 1998; 12: 1683-1691.
12. Ahn MY, Zhang ZG, Tsang W, et al. Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. Brain Res 1999; 837: 169-176.
13. Docagne F, Nicole O, Gabriel C, et al. Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-β1 against NMDA-induced Necrosis. Mol Cell Neurosci 2002; 21: 634-644.
14. Takahashi H, Uno S, Watanabe Y, et al. Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin. NeroReport 2000; 11: 1111-1115.
15. Kimura M, Soeda S, Oda M, et al. Release of plasminogen activator inhibitor-1 from human astrocytes is regulated by intracellular ceramide. J Neurosci Res 2000; 62: 781-788.
16. Obeid LM, Linardic CM, Karolak LA, et al. Programmed cell death induced by ceramide. Science 1993; 259: 1769-1771.
17. Soeda S, Iwata K, Hosoda Y, et al. Daunorubicin attenuates tumor necrosis factor-?-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. Biochim Biophys Acta 2001; 1538: 234-241.
18. Krystosek A, Seeds NM. Plasminogen activator release at the neuronal growth cone. Science 1981; 213: 1532-1534.
19. Pittman RN. Release of plasminogen activator and a calcium-dependent metallo-protease from cultured sympathetic and sensory neurons. Dev Biol 1985; 110: 91-101.
20. Qian Z, Gillbert ME, Colicos MA, et al. Tissue plasminogen activator is induced as an immediate-early gene during seizure kindling and long-term potentiation. Nature 1993; 361: 453-457.
21. Tsirka SE, Gualandris A, Amaral DG, et al. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377; 340-344.
22. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384: 123-124.
23. Krueger SR, Ghisu GP, Cinelli P, et al. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci 1997; 17: 8984-8996.
24. Osterwalder T, Contartese J, Stoeckli ET, et al. Neuroserpin, an axonally secreted serine protease inhibitor, EMBO J 1996; 15: 2944-2953.
25. Osterwalder T, Cinelli P, Baici A, et al. The axonally secreted serine protease inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998; 273: 2312-2321.
26. Hastings GA, Coleman TA, Haudenschild CC, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons: implication for the regulation of motor learning and neuronal survival. J Biol Chem 1997; 272: 33062-33067.
27. Rao JS, Rayford A, Morantz RA, et al. Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. J Neurooncol 1993; 17: 215-221.
28. Soeda S, Oda M, Ochiai T, et al. Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. Mol Brain Res 2001; 91: 96-103.
29. Soeda S, Imatoh T, Ochiai T, et al. Plasminogen activator inhibitor-1 aids survival of neuritis on neurons derived from pheochromocytoma (PC-12) cells. NeuroReport 2004; 15: 855-858.
30. Nakajima A, Yamada K, Zou L-B, et al. Inertleukin-6 protects PC12 cells from 4-hydroxynonenal-induced cytotoxity by increasing intracellular glutathione levels. Free Rad Biol Med 2002; 32: 1324-1332.
31. Jin KM, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000; 97: 10242-10247.
32. Gunn-Moore FJ, Tavare JM. Progress toward understanding the molecular mechanisms of neurotrophic factor signaling. Cell Signal 1998; 10: 151-157.
33. Harper SJ, LoGrasso P. Signalling for survival and death in neurons: the role of stress-activated kinases, JNK and p38. Cell Signal 2001; 13: 299-310.
34. Creedon DJ, Johnson EM, Lawrence JC. Mitogen-activated protein kinase-independent pathways mediate the effects of nerve growth factor and cAMP on neuronal survival. J Biol Chem 1996; 271: 20713-20718.
35. Klesse LJ, Meyers KA, Marshall CJ, et al. Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene 1999; 18: 2055-2068.
36. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001; 152: 741-751.
37. Farias-Eisner R, Vician L, Reddy S, et al. Expression of the urokinase plasminogen activator receptor is transiently required during priming of PC12 cells in nerve growth factor-directed cellular differentiation. J Neurosci Res 2001; 63: 341-346.
38. Hino H, Akiyama H, Iseki E, et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. Neurosci Lett 2001; 297: 105-108.
39. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32: 177-180.
40. Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1995; 1: 138-142.
41. Tucker HM, Kihiko-Ehmann M, Wright S, et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem 2000; 75: 2172-2177.
42. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits A?-induced neurodegeneration. J Neurosci 2003; 23: 8867-8871.
43. Soeda S, Shinomiya K, Ochiai T, et al. Plasminogen activator inhibitor-1 aids nerve growth factor-induced differentiation and survival of pheochromocytoma cells by activating both the extracellular signal-regulated kinase and c-Jun pathways. Neuroscience 2006; 141: 101-108.
44. Estus S, Zaks WJ, Freeman RS, et al. Altered gene expression in neurons during programmed cell death: identification of c-Jun as necessary for neuronal apoptosis. J Cell Biol 1994; 127: 1717-1727.
45. Dragunow M, Xu R, Walton M, et al. c-Jun promotes neurite outgrowth and survival in PC12 cells. Mol Brain Res 2000; 83: 20-33.
46. Zhou F-Q, Walter MA, Sinder WD. Turning on the machine: genetic control of axon regeneration by c-Jun. Neuron 2004; 43: 1-4.
47. Takeda M, Kato H, Takamiya A, et al. Injury-specific expression of activating transcription factor-3 in retinal ganglion cells and its colocalized expression with phosphorylated c-Jun. Invest Ophthalmol Vis Sci 2000; 41: 2412-2421.
48. Nakagomi S, Suzuki Y, Namikawa K, et al. Expression of the activating transcription factor 3 prevent c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and Akt activation. J Neurosci 2003; 23: 5187-5196.
49. Pearson AG, Gray CW, Pearson JF, et al. ATF3 enhances c-Jun-mediated neurite sprouting. Mol Brain Res 2003; 120: 38-45.
50. Lambert JC, Chartier-Harlin MC, Cottel D, et al. Is the LDL receptor-related protein involved in Alzheimer's disease? Neurogenetics 1999; 2: 109-113.
51. Degryse B, Neels JG, Czekay R-P, et al. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279: 22595-22604.